ADC 製造

相關產品資源

• Brochure: Biopharmaceutical and ADC Processing Portfolio

  The document outlines the complexities of Antibody Drug Conjugate (ADC) development and emphasizes the expertise and integrated services offered to advance ADCs to market efficiently.

• White Paper: Know your ADC’s Critical Quality Attributes

  The increased focus on cancer has led to the rapid development of antibody drug conjugates (ADCs), a highly effective class of oncology therapeutics with a projected global market value of $7.5 billion by 2025.

• White Paper: Commercializing Antibody-drug Conjugates: a CMO’s Journey

  In this white paper, we outline how our organization used over 12 years of experience to establish commercial-scale ADC manufacturing capabilities.

• Poster: Efficacy Screening of Antibody-Drug-Conjugates by Surface Plasmon Resonance

  The intro details the complexity and challenges in characterizing antibody-drug conjugates (ADCs) and the factors influencing their effectiveness, especially in tumor targeting. It also mentions a study that expands the investigation into linker and toxin variation and binding activities using Surface Plasmon Resonance (SPR).

• Poster: Novel Format Conjugates – Process and Analytical

  Bioconjugation technology have greatly improved the efficacy of treatments for diseases previously difficult to address with traditional ADC therapies, leading to a demand for clinical supplies.

• PDF: ADC Express™ Services for Best Candidate Selection

  As a leading CTDMO in the ADC space, we offer a rapid approach for developing ADC constructs and provide efficient bioconjugation capabilities for developers needing ADC library generation. Our ADC Express™ Service facilitates the transition to development and GMP manufacturing for candidates entering the clinic.

• White Paper: Benefits of Monodisperse and Activated PEGs in ADC Development

  The whitepaper highlights the use of PEGs to enhance solubility in ADC development, emphasizing the importance of ADCs in delivering drugs directly to tumors while minimizing damage to healthy tissue.

• White Paper: Use of Payload Core Compounds to Accelerate ADC Clinical Development Timelines

  ADCs treat diseases like cancer by targeting specific cells to minimize off-target toxicity. Eleven are approved, with hundreds in development.

• Technical Flyer: ADCore Payload Intermediates: Simplify Your Payload Synthesis

  ADCore products are cGMP quality advanced intermediates that help accelerate drug development efforts by reducing the number of development and manufacturing steps needed to produce Maytansinoid, Dolastatin, or Pyrrolobenzodiazepine (PBD)payloads.

• Technical Flyer: ChetoSensar™

  Our ChetoSensar™ Technology can help to improve the solubility of ADCs and provides access to highly hydrophobic novel payloads that might not be considered.

• Technical Flyer: Maytansinoid GMP Quality Payloads for Your Drug Conjugate Programs

  Our maytansinoid products aim to expedite your journey to the clinic. Offerings include GMP quality DM1-Mertansine for drug conjugate programs and MAYCore™ intermediate for simplified payload synthesis. These products feature high purity, free samples, and regulatory filing support, suitable for phase I clinical studies with valid processes.

• Brochure: Biopharmaceutical and ADC Process Application Guide

  Developing an Antibody Drug Conjugate (ADC) demands expertise in small and large molecule development, manufacturing, formulation, and testing.

• Data Sheet: Eshmuno^® CMX mix-mode chromatography resin
• Case Study: Complete Single-use ADC technology, from development to scale-up

  The global antibody-drug conjugate (ADC) market is rapidly expanding, with an estimated 22% compound annual growth rate (CAGR) from 2017 to 2022.

• Application Note: Compatibility of a Mobius^® Single-use Solution for ADC Processing

  ADCs, a fast-growing biomolecule class in oncology therapeutics, include a monoclonal antibody (mAb), linker, and cytotoxic payload, all contributing to therapeutic efficacy

• Poster: Mobius^® Single-use ADC Technology Supporting ADC Processing

  Our Mobius^® line provides a comprehensive single-use bioprocessing portfolio, featuring mixers, chromatography, and tangential flow filtration systems ideal for antibody drug conjugate production.

• Application Note: Pellicon^® Capsules for Ultrafiltration/Diafiltration of ADCs

  Tangential flow filtration (TFF) is crucial in antibody drug conjugate (ADC) manufacturing. Ultrafiltration (UF) concentrates the protein product, while diafiltration (DF) exchanges buffer and removes impurities.

• White Paper: ChetoSensar™- Overcoming the Solubility Challenges of Antibody-drug Conjugates

  The St. Louis (USA) manufacturing site offers over 35 years of experience in bioconjugation, APIs, excipients, and adjuvants manufacturing. With extensive analytical capabilities, dedicated compliance resources, and innovative manufacturing capabilities, the site assists customers worldwide in accelerating their drug development programs.

• Brochure: Process Development and Drug Manufacturing

  We provide comprehensive services for drug development and manufacturing, including technical and regulatory expertise and process development support.